Ipca Laboratories Ltd. has announced the acquisition of 100% share capital of Onyx Research Chemicals Ltd. holding Company of Onyx Scientific Ltd. through its wholly owned subsidiary Ipca Laboratories U.K. Ltd. The acquisition brings together two leading CMOs to better serve their customers on a global basis.
Onyx Scientific has been a premier chemistry solutions provider for over a decade and will continue to operate out of the Silverbriar (Sunderland, UK) facility under the Onyx Scientific trade name.
Ipca India provides CMO services through its Covenance business division. Onyx Scientific’s capabilities in chemistry services for Medicinal, Preclinical and Phase-I/II programs will dovetail effectively with Ipca’s capabilities in supporting Phase II to Commercial scale programmes.
Tony Flinn, chief executive officer at Onyx Scientific, said: “The combined entity of Onyx Scientific and Covenance division of Ipca will offer customers comprehensive solutions - Early development projects can be delivered from Onyx Scientific’s UK site with speed and flexibility while optimization, scale-up and competitive manufacturing for late phase projects can be carried out from Ipca’s locations in India.
“I can see a real take up in our services deriving from our ability to seamlessly take products from development into manufacturing,” he added.
Pranay Godha, executive director at Ipca, added “We are very excited about this venture as we can now offer integrated services across the pharmaceutical life cycle with optimal speed, quality and cost offering.”